Retinopathy of Prematurity and MicroRNAs
Authors:
- Giuseppe Maria AlbaneseGAGiuseppe Maria Albanese
- Giacomo VisioliGVGiacomo Visioli
- Ludovico AlisiLALudovico Alisi
- Marta ArmentanoMAMarta Armentano
- Francesca GiovannettiFrancesca Giovannetti
- Luca LucchinoLLLuca Lucchino
- Marco MarencoMMMarco Marenco
- Paola PontecorviPPPaola Pontecorvi
- Magda GharbiyaMGMagda Gharbiya
Open Access
- 7 February 2025
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 13 (2) , 400
Abstract
Retinopathy of Prematurity (ROP), a leading cause of blindness in preterm infants, arises from dysregulated angiogenesis and inflammation. Without timely intervention, ROP can progress to severe outcomes, including dense fibrovascular plaques and retinal detachment. MicroRNAs (miRNAs) regulate key pathways such as hypoxia response, VEGF signaling, and vascular remodeling. Studies have identified miRNAs (e.g., miR-210, miR-146a, and miR-21) as potential biomarkers and therapeutic targets. Preclinical evidence supports miRNA-based therapies (e.g., miR-18a-5p and miR-181a), targeting HIF-1α and VEGFA to mitigate neovascularization, with nanoparticle delivery systems enhancing stability and specificity. These strategies, combined with anti-VEGF agents, show significant potential for improving ROP management. While promising, miRNA therapies require validation in clinical trials to ensure safety and efficacy. This review discusses the role of miRNAs in ROP, highlighting their relevance as diagnostic and therapeutic tools.Keywords
This publication has 86 references indexed in Scilit:
- Neuroretinal and microvascular retinal features in dementia with Lewy body assessed by optical coherence tomography angiographyNeurological Sciences, 2024
- Laser versus Anti-VEGF: A Paradigm Shift for Treatment-Warranted Retinopathy of PrematurityOphthalmology and Therapy, 2023
- Diagnostic Performance of a Panel of miRNAs (OsteomiR) for Osteoporosis in a Cohort of Postmenopausal WomenCalcified Tissue International, 2021
- CircPDE4B inhibits retinal pathological angiogenesis via promoting degradation of HIF‐1α though targeting miR‐181cIUBMB Life, 2020
- Apelin Is Required for Non-Neovascular Remodeling in the RetinaThe American Journal of Pathology, 2012
- miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular StudyAtherosclerosis, 2011
- Developmental Anatomy of the Retinal and Choroidal Vasculature2010
- Retinopathy of prematurityAngiogenesis, 2007
- Regression of the hyaloid vessels and pupillary membrane of the mouseBrain Structure and Function, 1999
- Early Retinal Vessel Development and Iris Vessel Dilatation as Factors in Retinopathy of PrematurityArchives of Ophthalmology (1950), 1996